All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
Telitacicept is a novel fusion protein that inhibits both B lymphocyte stimulator and a proliferation-inducing ligand in active systemic lupus erythematosus.1 Below, we present a visual abstract summarizing key safety and efficacy outcomes of the phase IIb study (NCT02885610) assessing telitacicept in adult patients with active systemic lupus erythematosus.
How might telitacicept fit into the existing treatment landscape for patients with SLE?
During the Lupus Hub Steering Committee meeting, key opinion leaders gathered to discuss how telitacicept might be integrated into the existing treatment approach...
Efficacy and safety of telitacicept in patients with SLE: Results from a phase III trial
This article summarizes the key findings of a phase III trial on the efficacy and safety of telitacicept in patients with SLE.
Subscribe to get the best content related to lupus delivered to your inbox